Abstract：
The protein corona surrounding nanoparticles (NPs) offers exciting possibilities for targeted drug delivery. However, realizing this potential requires direct evidence of corona-receptor interactions in vivo; a challenge hampered by the limitations of in vitro settings. This opinion proposes that utilizing engineered protein coronas can address this challenge. Artificial coronas made of selected plasma proteins retain their properties in vivo, enabling manipulation for specific receptor targeting. To directly assess corona-receptor interactions mimicking in vivo complexity, we propose testing artificial coronas with recently adapted quartz crystal microbalance (QCM) setups whose current limitations and potential advancements are critically discussed. Finally, the opinion proposes future experiments to decipher corona-receptor interactions and unlock the full potential of the protein corona for NP-based drug delivery.
摘要：
围绕纳米颗粒（NPs）的蛋白质电晕为靶向药物递送提供了令人兴奋的可能性。然而,实现这一潜力需要体内电晕受体相互作用的直接证据;一个挑战阻碍了体外设置的局限性。这一观点提出，利用工程蛋白质冠可以解决这一挑战。由选定的血浆蛋白制成的人工冠状动脉在体内保留其特性，能够操纵特定的受体靶向。为了直接评估模拟体内复杂性的电晕受体相互作用，我们建议使用最近适应的石英晶体微天平（QCM）设置来测试人造冠，对其当前的局限性和潜在的进步进行了严格的讨论。最后,该观点提出了未来的实验来破译电晕-受体相互作用，并释放蛋白质电晕在基于NP的药物递送中的全部潜力。
